| Date | Title and Summary |
|---|---|
| Apr 18 2023 | CytoMed Therapeutics Limited Announces Closing of US$9,649,476 Firm Commitment Initial Public OfferingSingapore, April 18, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (“CytoMed” or the “Company”) (Nasdaq: GDTC), a pre-clinical biopharmaceutical company focused on developing novel cell-based immunotherapies for the treatment of human cancers... Read All |
| Apr 13 2023 | CytoMed Therapeutics Limited Announces Pricing of Initial Public OfferingSingapore - April 13, 2023 — CytoMed Therapeutics Limited ("CytoMed" or the "Company"), a pre- clinical biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers, today announced the pricing of its initial public offering ... Read All |